Abstract
Sulfamated 2-ethylestra compounds have demonstrated strong anticancer activity, high bioavailability and an ability to bypass liver metabolism by reversibly binding carbonic anhydrase (CA) II in erythrocytes. Another CA isoform, CA IX, is overexpressed in many cancers. The CA domain of CA IX is oriented extracellularly, which may permit targeting inhibitors to tumors. Presented here is the characterization of three 2-ethylestra compounds bound to both CA II and a CA IX mimic protein. Inhibition by 18O exchange showed that compound 16 demonstrated an approximately 12-fold higher affinity for CA II over CA IX mimic. Structurally, compounds 15 and 16 showed alternate binding modes between CA II and CA IX mimic, apparently due to a water-mediated hydrogen bond to the isozyme-specific residue 67. Though the specificity was demonstrated for CA II over CA IX, this study reveals insights that may be key to developing isozyme specific CA inhibitors for novel anticancer therapies.
Keywords: Carbonic anhydrase, Isozyme specific, Structure based drug design, 2-Ethylestra compounds, Anti-cancer therapy, Steroid sulfatase inhibitors, Sulfamated 2-ethylestra compounds, erythrocytes, liver metabolism, estrogen, colchicine binding site, apoptosis, anti-angiogenic, PISA server, CA isoforms, cancer
Letters in Drug Design & Discovery
Title: Characterization of Carbonic Anhydrase Isozyme Specific Inhibition by Sulfamated 2-Ethylestra Compounds
Volume: 8 Issue: 8
Author(s): Katherine H. Sippel, Andre Stander, Chingkuang Tu, Balasubramanian Venkatakrishnan, Arthur H. Robbins, Mavis Agbandje-McKenna, Fourie Joubert, Annie M. Joubert and Robert McKenna
Affiliation:
Keywords: Carbonic anhydrase, Isozyme specific, Structure based drug design, 2-Ethylestra compounds, Anti-cancer therapy, Steroid sulfatase inhibitors, Sulfamated 2-ethylestra compounds, erythrocytes, liver metabolism, estrogen, colchicine binding site, apoptosis, anti-angiogenic, PISA server, CA isoforms, cancer
Abstract: Sulfamated 2-ethylestra compounds have demonstrated strong anticancer activity, high bioavailability and an ability to bypass liver metabolism by reversibly binding carbonic anhydrase (CA) II in erythrocytes. Another CA isoform, CA IX, is overexpressed in many cancers. The CA domain of CA IX is oriented extracellularly, which may permit targeting inhibitors to tumors. Presented here is the characterization of three 2-ethylestra compounds bound to both CA II and a CA IX mimic protein. Inhibition by 18O exchange showed that compound 16 demonstrated an approximately 12-fold higher affinity for CA II over CA IX mimic. Structurally, compounds 15 and 16 showed alternate binding modes between CA II and CA IX mimic, apparently due to a water-mediated hydrogen bond to the isozyme-specific residue 67. Though the specificity was demonstrated for CA II over CA IX, this study reveals insights that may be key to developing isozyme specific CA inhibitors for novel anticancer therapies.
Export Options
About this article
Cite this article as:
H. Sippel Katherine, Stander Andre, Tu Chingkuang, Venkatakrishnan Balasubramanian, H. Robbins Arthur, Agbandje-McKenna Mavis, Joubert Fourie, M. Joubert Annie and McKenna Robert, Characterization of Carbonic Anhydrase Isozyme Specific Inhibition by Sulfamated 2-Ethylestra Compounds, Letters in Drug Design & Discovery 2011; 8 (8) . https://dx.doi.org/10.2174/157018011796576105
DOI https://dx.doi.org/10.2174/157018011796576105 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Tests for the Choice of Cancer Therapy
Current Pharmaceutical Design Limiting Functional Deficiency Following Stroke: Exploiting Different Stem Cell Reservoirs
Current Neuropharmacology Recent Advances and Future Directions in the Management of Metastatic Renal Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Vitamin D and Asthma: Scientific Promise and Clinical Reality
Current Respiratory Medicine Reviews The Calcium-Sensing Receptor as a Regulator of Cellular Fate in Normal and Pathological Conditions
Current Molecular Medicine Expansion of Umbilical Cord Blood for Clinical Transplantation
Current Stem Cell Research & Therapy Structural and Functional Evolution of the Translocator Protein (18 kDa)
Current Molecular Medicine Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Nanoparticles based on oleate alginate ester as curcumin delivery system
Current Drug Delivery Magnetic Nanoparticles: A Review on Stratagems of Fabrication an d its Biomedical Applications
Recent Patents on Drug Delivery & Formulation Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Current Drug Targets Ethosomal Hydrogel of Raloxifene HCl: Statistical Optimization & Ex Vivo Permeability Evaluation Across Microporated Pig Ear Skin
Current Drug Delivery HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry Ribosome-inactivating Proteins from Root Tubers and Seeds of Trichosan-thes kirilowii and Other Trichosanthes Species
Protein & Peptide Letters Editorial [Hot topic: Cancer Therapy: Are we Missing the Target? (Guest Editor: Paola Gazzaniga)]
Current Cancer Drug Targets Antidiabetic Oils
Current Diabetes Reviews Thymidine Phosphorylase and Fluoropyrimidines Efficacy: A Jekyl and Hyde Story
Current Medicinal Chemistry - Anti-Cancer Agents Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design Graphical Abstracts
Letters in Drug Design & Discovery